Neoadjuvant dostarlimab for resectable stage III colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colon cancer that can be removed with surgery, and it is stage T3-4, N0-2, or stage III (cancer has grown into or through the colon wall and may have spread to nearby lymph nodes, but not to other organs).
- Your tumor has a specific genetic makeup called 'MSS' or 'pMMR' (it is not the MSI-H type).
- You have not had any prior cancer treatment for this colon cancer.
- You are healthy enough to receive immunotherapy (your blood work and overall health are acceptable).
- If you could become pregnant, you agree to use effective birth control and are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (CAPEOX) is more effective than chemotherapy alone for people with a specific type of colon cancer (MMRp/MSS) that has not spread. It is given before surgery to shrink the tumor.
This study tests dostarlimab given before surgery for stage II or III colon cancer that has a specific DNA repair defect. It aims to shrink or control the cancer so that some people may be able to skip surgery if the results are good.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
Hear when a new Colon Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.